Management of Systemic Lupus Erythematosus (SLE) Flare
Introduction to SLE Flare Management
- The American College of Rheumatology recommends immediately initiating or increasing glucocorticoids based on severity for an SLE flare, with intravenous methylprednisolone pulses for severe organ-threatening flares or oral prednisone for mild-to-moderate flares, while ensuring the patient is on hydroxychloroquine and adding immunosuppressive agents to enable steroid tapering 1, 2
Immediate Assessment and Stratification
- Determine flare severity to guide treatment intensity, with mild-to-moderate flares characterized by constitutional symptoms, arthritis, rash, or mild serositis without major organ involvement 3, 4
- Severe/organ-threatening flares are characterized by active lupus nephritis, neuropsychiatric manifestations, severe cytopenias, cardiopulmonary involvement, or vasculitis 1, 5
Acute Flare Management by Severity
- For mild-to-moderate flares, oral prednisone 0.5-1 mg/kg/day can be used, with tapering over 2-4 weeks 1
- For severe/organ-threatening flares, pulse intravenous methylprednisolone provides an immediate therapeutic effect and allows lower starting doses of oral glucocorticoids 1, 2, 5
Concurrent Immunosuppressive Therapy
- Initiate or optimize immunosuppressive agents immediately to enable glucocorticoid tapering, with options including mycophenolate mofetil, azathioprine, methotrexate, and cyclophosphamide 1, 2, 4, 5
Hydroxychloroquine Therapy
- Ensure all patients are on hydroxychloroquine at ≤5 mg/kg real body weight, as this is the backbone therapy that reduces disease activity, prevents flares, and improves survival 1, 6
Organ-Specific Considerations
- For lupus nephritis flare, kidney biopsy is essential for diagnosis and treatment planning, with induction therapy including glucocorticoids plus mycophenolate mofetil or cyclophosphamide 1, 4
- For neuropsychiatric lupus flare, inflammatory mechanisms can be treated with high-dose glucocorticoids and cyclophosphamide 1, 3, 4
Glucocorticoid Tapering Strategy
- Target maintenance dose <7.5 mg/day prednisone, with goal of eventual withdrawal, as chronic use of glucocorticoids correlates with infections, osteonecrosis, irreversible damage, and increased mortality 1, 6
Monitoring During and After Flare
- At each visit, assess validated activity indices, anti-dsDNA, C3, C4 levels, complete blood count, creatinine, proteinuria, urine sediment, and screen for infections 1, 2, 3, 7